Palatin Technologies, Inc. (PTN) Stock: A Biotech Stock That’s Falling


Palatin Technologies, Inc. (PTN) is making a move down in the market today. The stock, one that is focused on the biotech industry, is presently priced at $1.21 after a move down of -9.70% so far today. In terms of biotech companies, there are a number of factors that have the ability to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent headlines surrounding PTN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-24-19 04:45PM Dow ekes out gain but fresh Iran sanctions drag broader stock market lower
04:19PM Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women
08:03AM Palatin’s stock rockets after FDA OK to market sexual desire disorder treatment
Jun-21-19 05:41PM AMAG stock rallies on FDA approval for drug to increase women’s sex drive
05:40PM FDA Approves New Drug Application for Vyleesi (bremelanotide injection)

Nonetheless, when making an investing decision, prospective investors should look at much more than just news, this is especially the case in the speculative biotechnology sector. Here’s what’s going on with Palatin Technologies, Inc..

Recent Moves From PTN

While a move toward the top in a single session, like what we’re seeing from Palatin Technologies, Inc. may cause fear in some investors, a single session move alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It is generally smart to look into trends experienced by the stock further out than a single trading day. In the case of PTN, here are the returns on investment that we’ve seen:

  • Past 5 Sessions – In the last week, PTN has generated a price change amounting to -11.68%.
  • Past Month – The ROI from Palatin Technologies, Inc. throughout the last 30 days has been -13.57%.
  • Quarterly – Over the last 3 months, the stock has generated a return on investment that works out to 25.61%
  • Past Six Months – In the last 6 months, we’ve seen a change that works out to 68.03% from the company.
  • YTD – Since the close of last year PTN has produced a return of 70.81%.
  • Annually – Finally, throughout the past full year, we’ve seen movement in the amount of 28.72% out of PTN. Over this period of time, the stock has traded at a high price of -30.46% and a low of 105.08%.

Key Ratios

Digging into a few ratios associated with a company generally gives prospective investors a view of how dangerous and/or potentially profitable a stock pick might be. Here are some of the most important ratios to think about when digging into PTN.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the stock is going to fall. Throughout the sector, biotechnology stocks can carry a higher short ratio. However, we also tend to see a lot of short squeezes in the industry. Nonetheless, in regard to Palatin Technologies, Inc., the stock’s short ratio is 5.78.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Basically, they measure the company’s abilities to cover its debts when they mature based on quick assets or current assets. Because many biotech many companies are reliant on the continuation of support from investors, the current and quick ratios can look upsetting. Nonetheless, several gems in the biotech space do have strong quick and current ratios. As it relates to PTN, the quick and current ratios add up to 4.20 and 4.20 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets owned by the company. as it relates to Palatin Technologies, Inc., that ratio comes in at 0.08.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of shares. Many clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotech industry, this is a very important ratio to think about. In this case, the cash to share value comes to 0.

Analyst Opinions With Regard To Palatin Technologies, Inc.

While it’s not a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their thoughts in order to validate your own opinions before making an investment decision in the biotech sector. Below are the recent moves that we have seen from analysts when it comes to PTN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-05-15 Reiterated Canaccord Genuity Buy $4 → $6
Jan-12-15 Reiterated ROTH Capital Buy $6 → $4
May-23-12 Initiated Noble Financial Buy
Jan-23-07 Initiated Next Generation Buy $5

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PTN, here’s what we’re seeing:

  • Institutional Investors – As it stands now, institutions own 19.80% of PTN. Nonetheless, it is worth noting that the ownership held by institutions has seen a move in the amount of -2.77% in the past 3 months.
  • Insider Moves – with regard to insiders, those close to the situation currently hold 2.61% of Palatin Technologies, Inc.. Their ownership of the company has seen a move of 0.00% in the last 3 months.

A Look At Share Counts

Traders tend to be interested in the amounts of shares both available and outstanding. With respect to Palatin Technologies, Inc., currently there are 207.02M and there is a float of 196.11M. These data mean that of the total of 207.02M shares of PTN currently in existence today, 196.11M are available to be traded by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PTN, the short percent of the float is 6.71%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0.11. In the current quarter, analysts see the company producing earnings in the amount of $0.06. Over the last 5 years, PTN has generated revenue in the amount of $478.50% with earnings coming in at 20.60%. On a quarter over quarter basis, earnings have seen movement of -639.80% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, based on what I am, I have the ability to learn by myself. However, I was made by a human and human beings play a crucial role in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but I am able to learn much faster when I have the help of a teacher. If you would to teach me something, I’d love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at data? If so, write a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here